Vilazodone HCl

CAS No. 163521-08-2

Vilazodone HCl( EMD 68843 (Hydrochloride) | SB659746A (Hydrochloride) )

Catalog No. M18100 CAS No. 163521-08-2

Vilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 35 In Stock
10MG 38 In Stock
50MG 53 In Stock
100MG 77 In Stock
200MG 113 In Stock
500MG 184 In Stock
1G 276 In Stock

Biological Information

  • Product Name
    Vilazodone HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Vilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.
  • Description
    Vilazodone HCl, a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.(In Vivo):Administration of 5-HT1A receptor agonists produce a characteristic behavioral syndrome that includes changes in posture, hind limb reduction, head weaving, tremors, forepaw treading, and straub tail. In the rat ultrasonic vocalizations test, stress-induced vocalizations are inhibited by Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (55 mg/kg po) at 120 and 210 min post dose. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (20-40 mg/kg ip), administered acutely or prophylactically (1 week prior to behavioral testing), attenuated stress induces potentiated startle but has no effect on stress potentiated anxiety response in the elevated plus maze. Interestingly, a lower dose of 10 mg/kg of Vilazodone Hydrochloride (EMD 68843 Hydrochloride) has the opposite effect in the startle response, indicating a somewhat unexplained bidirectional effect, and all doses produce a potentiation of the startle-induced stress response possibly suggestive of an anxiogenic-like response. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) also represents another option for the treatment of MDD.
  • In Vitro
    ——
  • In Vivo
    Administration of 5-HT1A receptor agonists produce a characteristic behavioral syndrome that includes changes in posture, hind limb reduction, head weaving, tremors, forepaw treading, and straub tail. In the rat ultrasonic vocalizations test, stress-induced vocalizations are inhibited by Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (55 mg/kg po) at 120 and 210 min post dose. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) (20-40 mg/kg ip), administered acutely or prophylactically (1 week prior to behavioral testing), attenuated stress induces potentiated startle but has no effect on stress potentiated anxiety response in the elevated plus maze. Interestingly, a lower dose of 10 mg/kg of Vilazodone Hydrochloride (EMD 68843 Hydrochloride) has the opposite effect in the startle response, indicating a somewhat unexplained bidirectional effect, and all doses produce a potentiation of the startle-induced stress response possibly suggestive of an anxiogenic-like response. Vilazodone Hydrochloride (EMD 68843 Hydrochloride) also represents another option for the treatment of MDD.
  • Synonyms
    EMD 68843 (Hydrochloride) | SB659746A (Hydrochloride)
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    5-HT1A| SSRI
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    163521-08-2
  • Formula Weight
    477.99
  • Molecular Formula
    C26H27N5O2·HCl
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 25 mg/mL 52.30 mM;
  • SMILES
    C1CN(CCN1CCCCc1c[nH]c2c1cc(cc2)C#N)c1cc2c(cc1)oc(c2)C(=O)N.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Dawson LA, et al. CNS Neurosci Ther, 2009, 15(2), 107-117.
molnova catalog
related products
  • Aristololactam I

    Aristololactam I has cytotoxic potency, mediated through the induction of apoptosis in a caspase 3-dependent pathway.

  • Secukinumab

    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

  • Spesolimab

    Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. It plays a crucial role in the immune system by reducing biomarkers associated with congenital Th1/Th17 and neutrophil pathways.